RICHMOND, British Columbia, Sept. 25, 2007 (PRIME NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) has the pleasure to announce that Dr. Stewart Sell, a member of BioCurex's Scientific Advisory Board since October 2005 -- has been awarded the prestigious ISOBM-Abbott award for his lifetime achievements in cancer research, immunology, developmental biology, and stem cell research. Dr. Sell's achievements go beyond research, since he is an excellent pathologist and a gifted teacher who has written text books that are currently used by medical students. He received a special award for 25 years of teaching cancer biology by the American Association of Cancer Research (AACR). Dr. Sell has published over 350 scientific papers and 14 books. In 1984 his paper on activation of lymphocytes by reaction of ligands with surface immunoglobulin was listed as a Citation Classic. He has been named both a Distinguished Alumnus of the School of Medicine (Hench Award) and a Legacy Laureate of the University of Pittsburgh (the highest honor for a Pitt graduate). In 1998 he was cited as a Distinguished Scientist by the IATMO. In 2005, he received the Rudolf Virchow Award (LeadershipMedica, Italy) and in 2007, his paper on cancer stem cells was cited as a Scientific Landmark publication by AACR.
A photo accompanying this release is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4215
Dr. Sell is presently the Senior Research Physician at the Wadsworth Center of the New York State Department of Health and the Ordway Research Institute, Albany, NY.
Dr. Moro, BioCurex's CEO stated: "It was a very pleasant surprise to see Dr. Sell presented with this prestigious award, but then, it is no surprise at all; his life-long dedication to fighting cancer and searching for knowledge is well known to everyone in the field. Dr. Sell is an exceptional man who excels in everything he does, while being extremely humble about it! In one of the social meetings held during the ISOBM congress, Stewart pulled out a saxophone and together with two other scientists who played the piano, played incredible jazz music to the delight of the 300+ people in the room!
"Dr. Sell will be directly involved with our therapeutic efforts against cancer and, in the upcoming weeks, he will be meeting with our scientific staff to discuss new therapeutic strategies based on the RECAF cancer marker. His profound knowledge of immunology, tumor biology and cancer stem cells will be of paramount importance in deciding future strategies."
Dr. Garry Abelev and Dr. Phil Gold, also members of our Scientific Advisory Board and discoverers of the first two cancer markers ever found (AFP and CEA respectively), are previous recipients of the ISOBM-Abbott award.
About the ISOBM:
ISOBM stands for "International Society for Oncodevelopmental Biology and Medicine" and is the leading international forum for cancer markers. In 2007, the ISOBM celebrated its 35th annual meeting. The ISOBM-Abbott award is presented by Abbott Laboratories to scientists in the international community -- not necessarily ISOBM members -- who have made an outstanding contribution to the fields of basic oncology or clinical oncology. The winners are selected by a scientific committee appointed by the ISOBM and independent from Abbott.
For more information about the ISOBM-Abbott awards, please visit www.isobm.org/awards.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
The photo is also available via AP PhotoExpress.
